pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 49 | Non-oncology: 31 Oncology: 18 |
| Under Consideration for Negotiation | 16 | Non-oncology: 11 Oncology: 5 |
| Completed Negotiations | 760 | With Letter of Intent: 655 Without agreement: 105 |
| Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Wainua | AstraZeneca Canada Inc. | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | |
| Omlyclo | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
| Venclexta | AbbVie Corporation | In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia | |
| Gazyva | Hoffmann-La Roche Ltd. | In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia | |
| TBC (infliximab) | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
| Repatha | Amgen Canada Inc. | Atherosclerotic cardiovascular disease | |
| Opdivo-Yervoy | Bristol Myers Squibb Canada Inc. | In neoadjuvant setting for resectable stage III melanoma. | |
| Opdivo-Yervoy | Bristol Myers Squibb Canada Inc. | In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy. | |
| Cabtreo | Bausch Health, Canada Inc. | Acne Vulgaris | |
| Ultomiris | Alexion Pharma GmbH | Generalized myasthenia gravis (gMG) |